| ATPC 0.1158 65.43% | MTEN 0.0332 -5.95% | OCG 0.0099 -16.10% | SOXS 2.0697 -9.22% | AUID 1.9199 93.44% | CJMB 4.03 259.82% | IVP 0.0514 -37.32% | ZSL 2.8799 2.31% | NVDA 189.4801 3.46% | SLV 83.88 -0.80% | SPHL 16.86 649.33% | INTC 49.04 0.66% | ASST 0.9901 -3.87% | DVLT 0.745 3.73% | BNKK 4.175 50.18% | TZA 5.9265 -3.79% | APLT 0.1 0.10% | SOXL 60.8798 9.93% | TQQQ 55.4888 3.08% | BYND 1.0415 8.28% | GRAB 4.37 -5.62% | BBAI 6.4 2.24% | ONDS 13.575 0.11% | IBRX 3.9 29.14% | DUST 5.735 -1.04% | NVD 6.9084 -6.77% | TSLL 18.4101 1.88% | EEM 58.3301 1.00% | TSLS 5.135 -1.06% | BITO 13.315 -1.81% | DNN 3.551 1.75% | AAL 15.735 3.93% | PLUG 2.315 -1.49% | MSTX 4.93 -5.19% | SPY 694.945 0.66% | AMD 236.845 5.92% | JDST 2.075 -1.43% | NOK 6.715 5.58% | IBIT 54.45 -1.79% | RZLV 4.7555 17.13% | FNGD 5.375 -2.45% | SIDU 3.745 -0.13% | XLE 47.815 -0.51% | QQQ 625.95 1.03% | GPUS 0.2932 -8.63% | VALE 14.795 1.27% | TSM 344.39 5.28% | TSLA 443.57 0.99% | ACHR 9.215 3.42% | SQQQ 64.8865 -3.07%

Lazard Ltd (NYSE:LAZ) Earnings Preview and Financial Health Analysis

Lazard Ltd (NYSE:LAZ), a leading financial advisory and asset management firm, is gearing up to release its quarterly earnings on October 23, 2025. The firm, known for its expertise in mergers and acquisitions, restructuring, and capital raising, competes with financial giants such as Goldman Sachs and Morgan Stanley. Analysts are estimating an earnings per share (EPS) of $0.44 and revenue of $726.25 million. The consensus EPS estimate has seen a downward revision of 1.8% over the past 30 days, potentially impacting investor sentiment.

The market's reaction to earnings estimate revisions is significant, as empirical studies suggest. Should Lazard's actual earnings surpass expectations, the stock might witness an upward trend. On the other hand, if the earnings disappoint, the stock could face a decline. The insights shared during the earnings call will be crucial for investors to gauge the sustainability of any immediate price changes.

Examining Lazard's financial metrics reveals its market valuation. The firm boasts a price-to-earnings (P/E) ratio of 15.67, a price-to-sales ratio of 1.52, and an enterprise value to sales ratio of 1.37. These figures indicate how the market values Lazard's earnings and sales.

The company's financial health is underscored by a debt-to-equity ratio of 0.70 and a current ratio of 1.89. These ratios suggest a balanced approach to financing its assets and the ability to cover short-term liabilities with short-term assets, respectively. As Lazard approaches its earnings release, these metrics offer a comprehensive view of its financial standing.

Published on: October 23, 2025